Chondrosarcoma of the jaw: a closer look at its management. by SAMMARTINO G. et al.
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chondrosarcoma is a malignant cartilaginous tumor
arely involving the mandible. The prognosis is gen-
rally poor depending on the degree of differentiation
nd the quality of the resection.
This article details the various methods of treat-
ent and provides some clarifications on the clinical
spects as well as the therapeutic approach.
Chondrosarcoma is classified by the World Health
rganization (WHO) as a malignant tumor with
ure hyaline cartilage differentiation1 characterized
y the formation of cartilage, but not of bone, by
umor cells.2
Chondrosarcoma accounts for approximately 10%
o 20% of all primary malignant bone tumors3 and,
xcluding multiple myeloma, represents the second
ost common primary bone malignancy after osteo-
arcoma.3
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2349The term chondrosarcoma describes a heteroge-
eous group of tumors with varying morphology and
linical history including conventional chondrosarco-
as that constitute 90% of all chondrosarcomas and
are subtypes that constitute the remaining 10%.4
nother large distinction is made between primary
hondrosarcomas that arise in a previously normal
one and secondary chondrosarcomas that arise in a
enign precursor such as an enchondroma or an os-
eochondroma. Conventional chondrosarcomas in-
lude primary central, primary periosteal (juxtacorti-
al, a rare variant of conventional chondrosarcoma
rising on the surface of metaphysis of long bones),
nd secondary (in Ollier’s disease and Maffucci syn-
rome); dedifferentiated, clear cell, and mesenchymal
onstitutes the rare subtype group. Table 1 shows
he main clinicopathologic features that distinguish
hese subtypes. It is notable that chondrosarcoma is
sually more aggressive in younger individuals than
n adults.5 The incidence of involvement of head
nd neck sites varies from 5% to 12%,6,7 with lar-
nx,8 thyroid cartilage, and arytenoids being the
ost common sites of occurrence. However, chon-
rosarcomas can occur in virtually all other sites of
he craniofacial compartment in which cartilage is
ound, such as the mandible, maxilla, and maxillo-
acial skeleton (nose and paranasal sinuses), as well
s at the base of the skull and in the nasophar-
nx.6,8-10 In the head and neck, chondrosarcomas
re slightly more common in men than in women,
nd primarily occur in the fourth to seventh de-
ades of life.8
tiology
The etiology of chondrosarcomas still remains un-
lear, and their management controversial. The myriad
f proposed methods of treatment include radical surgi-
al resection,11 local curettage,12 cryosurgery,13 chemo-
herapy,14 radiotherapy,15 and immunotherapy.16
It is known that chondrosarcoma of the maxillofa-
ial region is extremely rare. Fourteen cases in India17nd 35 cases of chondrogenic tumor over a period of
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2350 MANAGING CHONDROSARCOMA OF THE JAW0 years in Japan18 have been published. Paddison
nd Hanks19 have indicated that primary involvement
f the maxilla by this tumor is particularly rare,
hereas others claim the same frequency of involve-
ent between the maxilla and mandible.20,21 Pind-
Table 1. CLINICOPATHOLOGIC ASPECTS OF CHONDRO
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ammartino et al. Managing Chondrosarcoma of the Jaw. J Oraorg reported only 1 case of chondrosarcoma in an pleven year period in Denmark underlying the very
ow prevalence of this neoplasm.22 Interestingly, in-
ividual cases of maxillary chondrosarcomas have
een reported.23,24 However, very few sizeable stud-
es of chondrosarcomas of the mandible have been
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SAMMARTINO ET AL 2351The predilection of chondrosarcoma for the man-
ibular symphysis, coronoid, and condylar processes
ay be explained in part by embryological issues. In
act, the bones of the symphysis, coronoid, and con-
ylar processes ossify endochondrally, whereas the
orpus and ramus of the mandible undergo intramem-
ranous ossification. Thus, it has been suggested that
hondrosarcomas arise from primitive mesenchymal
ells, or from embryonic remnants of the cartilagi-
ous matrix.26,27
IGURE 1. A, The preoperative orthopantomogram shows an ill-d
ith cortical breakthrough and periostitis. B, The preoperative axia
hondroid matrix (devoid of osteoid matrix) and a thick cartilagino
he radiograph as well as soft tissue extension. C, Computed tom
ggressive chondroid tumor with similar imaging features status po
ame patient after subsequent wide local resection and reconstruc
Table 2. REPORTED PRESENTING SYMPTOMS OF CHON
Tumor Pain Dental
welling
ass
Significant Sharp
Dull
Loose t
Separat
Maloccl
Gingiva
Recent
ammartino et al. Managing Chondrosarcoma of the Jaw. J Oraammartino et al. Managing Chondrosarcoma of the Jaw. J Oral Maxiiagnosis
Clinically, these tumors may present with patholog-
cal fractures or are discovered incidentally on radio-
raphs. More frequently, symptoms such as gingival
leeding and paresthesia of the lower lip occur, as
ell as tooth mobility and/or loss of teeth (Table 2).
n other occasions, pain of referred dental origin
auses the patient to consult a dentist. These lesions
ay appear radiographically as osteolytic, with radi-
chondroid lesion along the left side of the mandibular symphysis
ted tomography scan of the same patient shows a solid tumor with
with areas of calcification and aggressive features as detailed on
y scan of the same patient demonstrates local recurrence of the
ttage of the primary tumor. D, Follow-up orthopantomogram of the
thout evidence of local recurrence.
ARCOMA OF THE JAW
oms Nasal Symptoms Headache
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2352 MANAGING CHONDROSARCOMA OF THE JAWlucent shadows with a wide zone of transition and
rregular/indistinct borders.27-29 Alternatively, they
ay demonstrate an ill-defined cloud-like matrix with
he calcified “whorls and arcs” typical of a chondroid
atrix plus or minus aggressive features such as en-
osteal scalloping, cortical disruption, periostitis,
nd/or soft tissue mass effect (Fig 1A). Computed
omography (CT) may be very helpful in determining
he presence (or lack) of chondroid matrix and the
steoid matrix as well as the extent of the lesion
ncluding infiltration of adjacent structures and tissues
hat may be poorly visualized on routine roentgeno-
rams (Figs 1B,C).30,31 This is a particularly important
ssue because many osteosarcomas of the jaw fre-
uently have chondroblastic differentiation which
ay cause confusion with chondrosarcomas.32,33 It
as been suggested that CT or magnetic resonance
maging (MRI) should be used to determine nodal
tage of head and neck tumors because clinical esti-
ation of nodal involvement is incorrect in up to 25%
f cases.34 CT and MRI are complementary tech-
iques in assessing bone cancers. CT is excellent in
haracterizing tumor matrix and cortical/periosteal
nvolvement. MRI is important in the assessment of
one marrow extension and the involvement of the
djacent soft tissue structures.35 Radiographic fea-
ures of central and peripheral chondrosarcomas may
ary depending on circumstances, such as presence
r absence of tumoral calcification, patterns of bone
estruction, encroachment on the cortex, and pres-
nce of periostitis. High grade (aggressive) chondro-
arcomas may show large areas of irregular or absent
alcification of the tumor and a poorly defined bound-
ry between normal and abnormal bone. Bone scans
how increased uptake of radionuclide in cases of
entral chondrosarcomas and reveal metabolically ac-
ive areas in peripheral chondrosarcomas. Whole
ody bone scans can also be used to identify meta-
tatic foci. Absence of uptake essentially rules out
alignant transformation of an osteochondroma. CT
canning is valuable in showing the extent of the
umor and may be able to define the thickness of the
Table 3. GRADING
Grade 1
ypercellular tumors with monomorphic
hyperchromatic nuclei and occasional
binucleation
Moderately
Moderate
and hyp
bundant matrix
ow mitotic count
ecrosis absent
ytologically indistinguishable from
benign enchondromasammartino et al. Managing Chondrosarcoma of the Jaw. J Oral Maxiartilaginous cap in peripheral chondrosarcomas. CT
s more sensitive than MRI for the detection of calci-
cations. MRI defines the full extent of tumor and is
articularly useful in anatomically complex areas.
hondroid lesions in general are of inhomogeneous
r homogeneous high signal intensity on T2-weighted
pin-echo images. Intravenous administration of gad-
linium compounds typically shows focal or diffuse
nhancement of signal intensity on T1-weighted fat-
uppressed sequences.
Diagnosis can only be established by histopatho-
ogic examination. However, histologically it can be a
ifficult task to differentiate benign and low-grade
alignant chondrogenic tumors due to the subtle
ifferences between the 2 lesions. Chondrosarcomas
re usually more cellular than benign enchondromas,
he hypercellularity may not be diffuse and it may be
imited to scattered areas. Chondrosarcomas when
ompared with benign chondroid lesions show more
ytological atypia, expressed by the variation in size
nd shape of neoplastic chondrocytes, along with
uclear hyperchromasia, pleomorphism, and fre-
uent binucleation. Myxoid changes with nonhomo-
eneous and “stringy” appearance are also frequent in
hondrosarcomas, whereas necrosis and increased
itotic activity are more frequent in higher-grade
umors.36 The single most important feature differ-
ntiating a malignant chondroma from a benign tu-
or is the permeative pattern of the former with true
nfiltration of the cortical and or the medullary bone,
nd /or extension into surrounding soft tissue; radiol-
gy plays a determinant role in the evaluation of this
eature. This is particularly important when dealing
ith chondroid tumors of small bones of hand and foot
here hypercellularity, hyperchromasia, binucleation,
nd myxoid changes also can be present in benign
umors.1,37 Prognostic factors include histologic
rade, tumor necrosis, mitotic activity, and myxoid
hanges. Histologic grading is the single most impor-
ant factor in predicting local recurrence and rate of
etastasis. Table 3 shows the principal parameters to
valuate in grading chondrosarcomas.
e 2 Grade 3
rcellular tumors
r pleomorphism
masia
High cellularity
Prominent cellular pleomorphisms
and nuclear atypia
Decreased matrix
Mitoses and necrosis frequentGrad
hype
nuclea
erchrollofac Surg 2008.
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SAMMARTINO ET AL 2353Five-year survival is about 90% for grade 1 chondro-
arcomas and around 50% for combined grade 2 and
chondrosarcomas. Occasionally, chondrosarcomas
how the coexistence of various histologic grades in
he same tumor; it is appropriate in these cases to
uantify the different grades by percentage.38
Differential diagnosis must be based on studying
he cellular structure, rather than the calcified portion
f the tumor (Fig 2).27,29 In this respect image-guided
iopsy may help in treatment planning. In this disease
he cartilaginous cells are large, irregular, and have
yperchromatic nuclei, and the matrix shows a tran-
ition from myxoid to chondroid tissue.9,39 At a later
tage of the disease process, the tumor may become
ore immature and of a higher histological grade,
ith a more fibrous, myxomatous, or mesenchymal-
ppearing matrix.40
reatment
Because of the rarity of chondrosarcoma of the jaw
here are no established evidence-based treatment
rotocols. For this reason, many of the current treat-
ent strategies for this disease have been extrapo-
ated from protocols developed and tested for chon-
rosarcomas of other more typical locations outside
f the head and neck region or other types of sarco-
as. Chondrosarcoma is generally treated with a multi-
odal approach: wide en-bloc resection,11,41-44 local
urettage,12 cryotherapy,12 chemotherapy,14 radiother-
py,15,19,45 and immunotherapy.16 Treatment depends
n the size of the tumor and extent of the lesion.
dequate surgical resection remains the gold standard
or the treatment of the jaw chondrosarcoma.11 For
atients with resectable lesions it represents the pri-
ary modality of treatment.12,46,47 The resection area
ust be as wide as possible. Surgical clear margins are
ery important for favorable prognosis and for a de-
reased risk of recurrence (Figs 1C,D). Ideal initial
IGURE 2. Low grade chondrosarcoma. Hyaline matrix with ple-
morphic neoplastic chondrocytes, including a binucleate cell in
acunae.
ammartino et al. Managing Chondrosarcoma of the Jaw. J Oral
axillofac Surg 2008.esection includes bone margins of 2 to 3 cm sur-
S
Mounding the lesion even when the cortex is intact.46
his surgical approach often requires extensive abla-
ive procedures that can compromise major func-
ional and esthetic elements and necessitates the per-
ormance of complex bone reconstructive techniques
Fig 3).44 The intralesional excision–curettage of
arge lesions, combined with a powerful local adju-
ant radiation therapy, can be advocated in these
ases even if this approach is not curative.12,42 Cryo-
urgery is suggested for the treatment of grade 1
hondrosarcoma.13,48,49 Many studies seem to agree
hat the risk of local recurrence is limited in cryosur-
ically treated grade 1 chondrosarcoma. Additionally,
unctional results are improved when compared with
hose obtained with marginal or wide excisions. From
n oncological point of view, results obtained from
he combined approach of cryosurgery and intrale-
ional excision are similar to those of marginal exci-
ion and even better than those of wide excision of
rade 1 chondrosarcoma.13 The use of cryosurgery
an be associated with complications such as infec-
ion, embolism, and neuropathy; infection is the most
ommon associated risk in the head and neck region,
specially when cryosurgery is combined with recon-
tructive procedures. Even though surgery is the treat-
ent of choice for this disease, high recurrence rates
ave been observed with surgery alone and, as a
esult, combined treatment of surgery with radiation
nd/or chemotherapy has been suggested. In sum-
ary, the real role of these adjuvant therapies is still
ontroversial, because there have been few reported
ases with sufficient follow-up to confidently deter-
ine outcomes. Some studies have shown better
IGURE 3. Surgical access showing the chondrosarcoma in the
eft mandible.ammartino et al. Managing Chondrosarcoma of the Jaw. J Oral
axillofac Surg 2008.
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2354 MANAGING CHONDROSARCOMA OF THE JAWrognosis using combined treatments of surgery and
rradiation15,19,45; others indicate that the benefits of
his combined treatment remain unproven.28,29,43
any authors believe that chondrosarcoma is a radio-
esistant tumor because of a prolonged response time
o irradiation12,50 which appears to not provide any
urvival benefits.41 Irradiation therapy could have a
ole in some instances, such as in the case of incom-
letely resected or inoperable tumors.42,44 Some au-
hors suggest that the combination of radiation ther-
py and chemotherapy is synergistic in reducing the
iability of tumor cells that may disperse during sur-
ical procedures and to control rapidly growing tu-
ors as neoadjuvant therapy before surgery.19,43
Because of the improved outcome of adjuvant che-
otherapy combined with surgery in cases of sar-
oma of the jaw 46 some investigators have taken into
onsideration the use of this regimen also in chondro-
arcoma of the jaw. However, because of the lack of
pecific data, the efficacy of this type of treatment is
ot well established, even if the majority of the stud-
es indicate no significant therapeutic benefits from
he use of chemotherapeutic agents.16,41,42,45,46,51,52
uestions persist, however, regarding the use and
iming of chemotherapy before or after surgery. Most
urgeons would agree on neoadjuvant chemotherapy
n cases of chondrosarcoma, because it is intuitive
hat clear margins would otherwise be unobtainable
ithout undue morbidity. Crawford et al,14 using che-
otherapy as neoadjuvant treatment, suggested that
lthough combined chemotherapy did not decrease
he size of the tumor, it inhibited tumor growth and
pread. The use of chemotherapy postoperatively is
lso controversial in the case of clear pathological
argins. Of course, information such as tumor dis-
ance from the margins and histological grading is
seful in the decision-making process.46 Although, in
eneral, chondrosarcomas have been thought to be
esistant to chemotherapy, a great interest has
merged about its use in metastatic disease and in
edifferentiated forms. Mitchell et al53 suggested the
ossible role of chemotherapy for the dedifferenti-
ted forms; the dedifferentiated component is a high
rade spindle and/or pleomorphic sarcoma (Table 1),
nd a (at times dramatic) positive response has been
ocumented for other high grade sarcomas treated
ith chemotherapy. However, Dickey et al54 have
iscussed the inherent risks of chemotherapy and
oncluded it is not beneficial in improving the long-
erm survival or distant metastasis control. This illus-
rates that a more effective adjuvant method needs to
e implemented; molecular genetics represents a field
f investigation that may hold hopes for this aim.
ecent studies in the molecular biology of chondro-
arcoma have pointed to the role of progressive ac-
uired molecular abnormalities in the evolution ofnchondromas to low grade chondrosarcomas and
rom these to high grade chondrosarcomas; other
athways seems to be involved in the de novo devel-
pment of chondrosarcomas from “normal” cartilage.
ike other tumor types, chondrosarcoma demon-
trates a peculiar antigenicity that may support an
mmunologic etiology. Several molecular targets have
een identified for future development of new adju-
ant therapies;1,4 some of these may include hor-
onal antiestrogenic therapy,4,55 antiangiogenesis
reatment with selective cyclo-oxygenase-2 (COX-2)
nhibitors,4,56 and inhibition of parathyroid hormone-
ike hormone (PTHLH) pathway with Bcl-2 antisense
herapy.4,57 More studies are needed to confirm
he hypothesis of the previously mentioned multistep
enetic model for the arising and evolution of chon-
rosarcomas and to explore the possibility in the
uture of immunotherapy in the treatment plan of this
isease.16
In our opinion, the treatment plan for chondrosar-
oma of the jaws, like treatment plans for most of the
alignant tumors of the oral and maxillofacial region,
s restricted to radical surgery which provides pa-
ients with the greatest chance of long term survival
nd cure. High-energy irradiation, chemotherapy, im-
unotherapy, and cryosurgery may be useful as adju-
ant forms of therapy in rare instances, but have not
et been extensively studied relegating them to sec-
ndary lines of therapy for chondrosarcomas of the
aw.
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